FDA to weigh lifting restrictions on some MAHA-favored peptides
Quick Insights
The Bottom Line
The FDA will consider lifting restrictions on certain peptide injections favored by MAHA for various conditions.
How This Affects You
If approved, this could ease access to treatments for conditions like ulcerative colitis, wound healing, and obesity for patients.
AI Summary
The Food and Drug Administration (FDA) announced it will convene an outside advisory panel in July to consider lifting restrictions on certain peptide injections. These peptides are currently restricted due to safety concerns but are favored by MAHA (Medical and Health Association) for various conditions. The agency is specifically discussing whether to permit compounding pharmacies to manufacture peptides for uses such as ulcerative colitis, wound healing, and obesity. This move could significantly ease access to these treatments for patients if the advisory panel recommends approval. The FDA's decision follows a Federal announcement regarding the meeting.
What's Being Done
The FDA will convene an outside advisory panel in July to discuss the restrictions.
Source Coverage Map
2 of 43 tracked sources covered this story
Following this story?
Get notified when new coverage appears
Other Sources Covering This Story
1 sourceMultiple outlets have reported on this story. Compare perspectives from different sources.
This article is part of a story we're tracking:
Should this be getting more attention?
You Might Have Missed
Related stories from different sources and perspectives
HealthFDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters
The Food and Drug Administration will hold a meeting this summer to consider easing restrictions on more than a half dozen peptide injections, a group of unapproved therapies that have become popular among wellness influencers, fitness gurus and celebrities.
HealthRFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban
HealthFDA Commissioner Marty Makary breaks down Trump's executive order on psychedelics
President Trump has signed an executive order to expand research into psychedelic drugs for mental health treatment. Dr. Marty Makary, commissioner of the Food and Drug Administration, joins CBS News to discuss.
HealthBurn treatment for Gaza children threatened by Israeli restrictions
Burn treatment for Gaza children threatened by Israeli restrictions
PoliticsWhat to Know About Trump’s New Executive Order on Psychedelic Drugs
The order calls for the FDA to give expedited consideration to certain psychedelic drugs.
HealthPopular weight loss medications linked to hidden side effects, study finds
The study found 4% of users reported "menstrual irregularities," according to Neil Sehgal, the study's first author.
Louisiana gunman had sought mental health treatment, relatives say
The man who killed eight children and wounded two women in Louisiana had sought mental health care from Veterans Affairs.
Did this story change how you see things?
Stories like this only matter when people see them. Help us get verified journalism in front of more eyes.
The Verity Ledger curates verified investigative journalism from trusted sources only.
See our sourcesMost Read This Week
Report: Merck’s blockbuster cancer drug topped $200,000 a year under Trump
One in three Americans forced to make financial sacrifices for health coverage
Airline mega-merger story is all about Trump
Pope blasts ‘tyrants’ ravaging the Earth during his visit to Cameroon - AP News
Justice Jackson chides Supreme Court conservatives over 'oblivious' pro-Trump emergency orders - AP News
